Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$59.33 USD
-1.10 (-1.82%)
Updated Oct 4, 2024 12:50 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 29% (73 out of 251)Zacks Sector Rank
Top 13% (2 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.80 | 1.37 | 9.99 |
Current Quarter Estimate | 0.99 | 2.88 | 61.00 |
Year Ago Quarter Estimate | 0.75 | -4.93 | 54.84 |
Next Quarter Estimate | 1.26 | 3.66 | 63.00 |
Next Year Estimate | 4.73 | 23.73 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 42.60 | 17.60 | 15.67 |
Next Year | 19.75 | 10.00 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | 28.00 | 21.50 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 18.48 | -6.83 |
Price/Book (MRQ) | 26.57 | 2.03 |
Price/Cash Flow (MRFY) | 19.02 | 16.44 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 38.62% | -163.24% |
Return on Equity (TTM) | 195.80% | -61.40% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.